Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Colorectal Neoplasms × tucatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Cetuximab 5 Bevacizumab 4 pembrolizumab 3 Leucovorin 3 Irinotecan 3 Fluorouracil 3 trifluridine tipiracil drug combination 2 trastuzumab deruxtecan 2 encorafenib 2 Oxaliplatin 2 HMPL-013 2 tucatinib 1 sotorasib 1 regorafenib 1 pralsetinib 1 larotrectinib 1 entrectinib 1 binimetinib 1 adagrasib 1 Trastuzumab 1 Panitumumab 1 Nivolumab 1 Levoleucovorin 1 Ipilimumab 1 IFL protocol 1 Capecitabine 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Seagen Inc.

Phase 2 Completed

117 enrolled 21 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡